Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits
暂无分享,去创建一个
Hong Wang | Fan Wang | Jin Yang | D. Dong | Jiao Yang | Xiaoai Zhao | Ran Ran | Ling-xiao Zhang | Mi Zhang | Yingying Ma | Le Wang | Juan Zhang | Qiaoyan Liu | Shujuan He
[1] M. Kudo,et al. Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study. , 2023, Journal of Clinical Oncology.
[2] Qiong-wen Zhang,et al. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study , 2023, Frontiers in Pharmacology.
[3] X. Bai,et al. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial , 2022, Breast Cancer Research and Treatment.
[4] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis , 2022, Cancer discovery.
[5] T. Szekeres,et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial , 2022, Nature Medicine.
[6] A. Toga,et al. A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes , 2022, Journal of Neuro-Oncology.
[7] S. Rajkumar,et al. Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches , 2022, Diagnostics and therapeutics.
[8] S. Chandarlapaty,et al. Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Awada,et al. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis , 2022, ESMO open.
[10] A. Jacobson. Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer , 2022, The oncologist.
[11] Ming Yan,et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. , 2022, The Lancet. Oncology.
[12] P. Brown,et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Loi,et al. Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] E. Zhou,et al. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data , 2021, Clinical Cancer Research.
[15] L. Pusztai,et al. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. , 2021, The oncologist.
[16] N. Ibrahim,et al. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Ying Cheng,et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.
[18] A. Giannoudis,et al. The genomic landscape of breast cancer brain metastases: a systematic review. , 2021, The Lancet. Oncology.
[19] H. Yao,et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study , 2020 .
[20] C. Anders,et al. HER2‐positive breast cancer brain metastasis: A new and exciting landscape , 2020, Cancer reports.
[21] P. Ellis,et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] E. Winer,et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Souweidane,et al. B7–H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors , 2019, Translational oncology.
[24] Wei Li,et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Bertucci,et al. A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases , 2019, Cancers.
[26] E. Winer,et al. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Gnant,et al. Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases , 2019, Clinical Cancer Research.
[28] Xin Li,et al. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[29] A. Bardelli,et al. Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases , 2017, ESMO Open.
[30] Peng Yuan,et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Adrian V. Lee,et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.
[32] Xiaoyan Chen,et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[33] A. Viale,et al. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Agatsuma,et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.
[35] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[36] K. Blackwell,et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] K. Blackwell,et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Yun-di Guo,et al. B7-H3 expression in breast cancer and upregulation of VEGF through gene silence , 2014, OncoTargets and therapy.
[39] H. Iwata,et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis , 2014, Breast Cancer Research and Treatment.
[40] S. Duffy,et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer , 2013, Breast Cancer Research.
[41] M. Westphal,et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.
[42] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[43] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[44] H. Harputluoglu,et al. Breast cancer subtypes and outcomes of central nervous system metastases. , 2011, Breast.
[45] Cyrus Chargari,et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. , 2011, International journal of radiation oncology, biology, physics.
[46] H. Rugo,et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.
[47] L. Crinò,et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Baselga,et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] B. Leyland-Jones. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] R. Greil,et al. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.
[52] M. Milella,et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.
[53] A. D. Van den Abbeele,et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] N. F.,et al. Long Survival in a Patient with Brain Metastases from Breast Cancer , 2008, Clinical medicine. Oncology.
[55] N. Harbeck,et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.
[56] J. Mackey,et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] C. Platini,et al. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. , 2006, The Lancet. Oncology.
[58] R. Gelber,et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] E. Winer,et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] C. Szczylik,et al. Central nervous system metastases in breast cancer patients administered trastuzumab. , 2005, Cancer treatment reviews.
[61] A. Howell,et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.
[62] OUP accepted manuscript , 2022, The Oncologist.
[63] L. Lou,et al. Discovery and development of pyrotinib : A novel irreversible EGFR / HER 2 dual tyrosine kinase inhibitor with favorable safety pro fi les for the treatment of breast cancer , 2017 .
[64] W. Gradishar,et al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] M. Campone,et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.
[66] E. Winer,et al. Ten years of HER2-directed therapy: still questions after all these years , 2008, Breast Cancer Research and Treatment.